Home › Funds › Davern Capital Partners, LP › GENB
Davern Capital Partners, LP position in GENB
Generate Biomedicines Inc · Health Care
Davern Capital Partners, LP reported holding 824,679 shares of GENB (Generate Biomedicines Inc) in its Q3 2026 13F filing — a position valued at US$12.4M, representing 2.41% of its reported portfolio and ranking #15 among its reported holdings. Davern Capital Partners, LP has disclosed GENB holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How Davern Capital Partners, LP's GENB position evolved
Davern Capital Partners, LP first disclosed a stake in GENB in Q1 2026 at 591,800 shares (US$7.4M). The position peaked in Q2 2026 at 824,679 shares, worth US$13.9M. Across 3 filings, Davern Capital Partners, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 824,679 shares valued at US$12.4M. Notable position changes include a 39% increase in Q2 2026 (shares fell 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 591.80K | $7.40M | New |
| Q2 2026 | 824.68K | $13.91M | Add |
| Q3 2026 | 824.68K | $12.39M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GENB and 13F data
GENB (Generate Biomedicines Inc) is a Health Care company. 96 other funds we track also report a position in GENB — the largest reported positions include Flagship Pioneering, LLC (US$1.06B), BRAIDWELL LP (US$55.4M), ARCH Venture Management, LLC (US$32.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GENB
- Flagship Pioneering, LLC 62.67M sh · $1.06B · Q2 2026
- BRAIDWELL LP 3.28M sh · $55.40M · Q2 2026
- ARCH Venture Management, LLC 1.94M sh · $32.80M · Q2 2026
- HARBOURVEST PARTNERS LLC 1.72M sh · $29.05M · Q2 2026
- BANQUE PICTET & CIE SA 1.77M sh · $26.63M · Q3 2026
- Harvard Management Company 1.11M sh · $18.74M · Q2 2026
- HARVARD MANAGEMENT CO INC 1.11M sh · $18.74M · Q2 2026
- NVIDIA CORP 833.33K sh · $14.06M · Q2 2026
More on Davern Capital Partners, LP
FAQ
How long has Davern Capital Partners, LP held GENB?
Davern Capital Partners, LP has disclosed GENB holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Davern Capital Partners, LP's current position in GENB?
As of Q3 2026, Davern Capital Partners, LP holds 824.68K shares of GENB (Generate Biomedicines Inc), valued at $12.39M, representing 2.41% of its reported portfolio and ranking #15.
Has Davern Capital Partners, LP been buying or selling GENB?
In the latest 13F filing (Q3 2026), Davern Capital Partners, LP held unchanged its position in GENB. The position peaked in Q2 2026 at 824.68K shares.
Which other funds hold GENB?
Other major institutional holders of GENB include Flagship Pioneering, LLC, BRAIDWELL LP, ARCH Venture Management, LLC, among 96 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.